CN101254203A - Pharmaceutical combination for curing acute radiation dermatitis - Google Patents
Pharmaceutical combination for curing acute radiation dermatitis Download PDFInfo
- Publication number
- CN101254203A CN101254203A CNA2008100547785A CN200810054778A CN101254203A CN 101254203 A CN101254203 A CN 101254203A CN A2008100547785 A CNA2008100547785 A CN A2008100547785A CN 200810054778 A CN200810054778 A CN 200810054778A CN 101254203 A CN101254203 A CN 101254203A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- pharmaceutical composition
- radiodermatitis
- oryzanol
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating acute radiodermatitis, and comprises polyriboinosinic -polyribocytidylic acid 10-20mg, vitamin A 20,000-50,000IU and oryzanol 10-100mg. The above ingredients can be prepared into 50ml solution with a proper amount of distilled water and ethanol. Through clinic experiments, it is proved that the inventive composition can be used for treating acute radiodermatitis while continuing conducing radiotherapy, so as to ensure the anticipated tumor treatment effect, and also has therapeutic effect on chronic radiodermatitis. The inventive pharmaceutical composition has only therapeutic action on diseased tissues and has no any damage to healthy tissues; has antiphlogistic, antiallergic, radioactive rays resisting, analgesic, antipruritic and skin growth promoting effects; and has the advantages of no sedatives, no analgesics, no hormones, quick action, high cure rate, no recurrence, and no toxic or side effects.
Description
Technical field
The present invention relates to a kind of medicine, especially a kind of pharmaceutical composition for the treatment of acute radiodermatitis.
Background technology
Radiodermatitis is curing dermal radio lesions or radiation burn again, be meant that various types of ionizing radiation comprise that microgranule wavelet or electron waves act on human body surface, cause any macroscopic early stage of skin and adnexa thereof or late period pathological changes, can be divided into acute and two kinds of chronic radiodermatitis.Acute radiodermatitis is meant that the part is subjected to once or the caused skin acute injury of heavy dose of (X, γ, β ray) external exposure repeatedly in the short time (a few days).Early stage performance: the slight pigmentation of skin, erythema, pruritus, pain or edema.Late period performance: ooze out, blister, erosion, ulcer or necrosis.Can be divided into four degree according to GBZ106-2002 radioactive skin medical diagnosis on disease standard, i.e. I ° of slight pigmentation of skin or hair follicle pimple; II ° of erythema or depilation; III ° of erythema, blister, burn feeling, pain or pruritus; IV ° of skin numbness, blister, erosion, ulcer or necrosis etc.
Treatment principle according to GBZ106-2002 radioactive skin medical diagnosis on disease standard is: break away from radiation source immediately, removing is suspected to have the radionuclide contaminant, strengthen nutrition, infection, sedation-analgesia, keep water-electrolyte balance, the application of immunostimulant and be coated with Egersund ointment, boric acid water, povidone iodine or laser therapy etc. outward.Your safe, black Jiang Dan of report external art and Jin Yintai or JINGWANHONG burn cream are also arranged.But proceed radiocurable when not having a family clearly to be reported in the treatment acute radiodermatitis.And, continuing radiocurable problem if in the treatment acute radiodermatitis, can't resolve for tumor patient, expection is very remote for tumor treatment.
Summary of the invention
Purpose of the present invention is for overcoming above-mentioned weak point, and provide a kind of pharmaceutical composition for the treatment of acute radiodermatitis, in the treatment acute radiodermatitis, can proceed radiotherapy, guarantee the tumor treatment expection, and can thoroughly effect a radical cure acute radiodermatitis.
The present invention treats the pharmaceutical composition of acute radiodermatitis, and its component is polyinosini 10-20mg, vitamin A 2-5 ten thousand U, oryzanol 10-100mg, and said components is mixed with the 50ml solution with an amount of distilled water and ethanol.
As a kind of improvement of the present invention, also add vitamin B in the component
1100-500mg.
As a kind of improvement of the present invention, also add vitamin B in the component
650-500mg.
As a kind of improvement of the present invention, also add GBF skin growth factor 100-500mg in the component.
As a kind of improvement of the present invention, also add metronidazole 100-500mg in the component.
As a kind of improvement of the present invention, can select vitamin B in the component
1100-500mg, vitamin B
6Any two kinds, three kinds or four kinds among 50-500mg, GBF skin growth factor 100-500mg, the metronidazole 100-500mg add simultaneously.
As of the present invention a kind of preferred, the drug regimen composition formula of treatment acute radiodermatitis is: polyinosini 10-20mg, vitamin A 2-5 ten thousand U, vitamin B
1100-500mg, vitamin B
650-500mg, oryzanol 10-100mg, GBF skin growth factor 100-500mg, metronidazole 100-500mg, adding distil water, ethanol are mixed with solution 50ml to eosin more in right amount.
The compound method that the present invention treats the pharmaceutical composition of acute radiodermatitis is: with ethanol vitamin A and eosin are dissolved, after oryzanol, metronidazole porphyrize are ground with the GBF skin growth factor again, with polyinosini, vitamin B
1, vitamin B
6Injection is dissolved in together, behind the mix homogeneously, gradually with dissolve with ethanol good vitamin A and eosin mix homogeneously, add distilled water again and make pale red solution 50ml, promptly get pharmaceutical composition of the present invention.In addition, can inventor's pharmaceutical composition be made solution, spray, cream, Emulsion, ointment or the gel that is suitable for topical or passes through skin or mucosa absorption administration according to the known method in pharmaceuticals industry field.When the present invention uses, with local affected part handle clean after, medicinal liquid evenly is applied to diseased region get final product, use continuously every day 3-5 time, formed a scab in 3 days, began decrustation in 7 days and heal.
In addition, also add different components among the present invention, comprise antibiotic, cell growth factor, immunostimulant or regulator etc., in treatment,, prepare the medicine of heterogeneity according to different patients' the different state of an illness with collaborative or assosting effect.As the common practise of this area, the medicine and the consumption thereof of concrete compatibility can obtain by conventional optimization test.The antibiotic powder or other medicaments that add when needing are dissolved in water-bearing media or other appropriate carriers or the substrate, with gained solution and suitable substrate or excipient uniform mixing, make various dosage forms then.
The present invention treats in the pharmaceutical composition component of acute radiodermatitis, antitoxin, enhancing immunity effect that polyinosini has; Vitamin B
6But radiotherapy disease, acne, and has antibacterial action; The GBF skin growth factor has the effect that promotes cell differentiation propagation, acceleration skin growth; Oryzanol can be nursed one's health skin growth, and the title of " beauty treatment is plain " is arranged.The present invention can proceed radiotherapy through clinical case verification in the radiotherapy dermatitis, guaranteed the tumor treatment expection, and can thoroughly effect a radical cure acute radiodermatitis, and is effective equally to chronic radiodermatitis.The component of medicine of the present invention mostly is nutrient, has the metabolism of regulating tissue, strengthens the immunocompetence and the adaptive capacity of tissue, and reaches the equilibrium of supply and demand of tissue, only pathological tissues is had therapeutical effect, and health tissues is not had any damage.Do not contain the calmness agent that relieves the pain in the medicine, do not contain hormone, have antiinflammatory, antiallergic, anti-lonizing radiation, the itching relieving effect that relieves the pain, promote skin growth, instant effect, cure rate does not absolutely recur without any side effects and untoward reaction.
The specific embodiment
Embodiment 1
Behind oryzanol 10mg porphyrize, 10mg is dissolved in polyinosini, behind the mix homogeneously, adds gradually with good vitamin A 20,000 U of dissolve with ethanol, adds distilled water again and is mixed with the 50ml solution.
Embodiment 2
Behind 50mg oryzanol porphyrize, with 15mg polyinosini, 100mg vitamin B
1Injection is dissolved in together, behind the mix homogeneously, adds gradually with good vitamin A 30,000 U of dissolve with ethanol, adds distilled water again and is mixed with the 50ml solution.
Embodiment 3
Press last routine method with polyinosini 20mg, vitamin A 50,000 U, oryzanol 100mg, vitamin B
6The 50mg adding distil water is mixed with solution 50ml.
Embodiment 4
Behind oryzanol 10mg and GBF skin growth factor 100mg porphyrize, 10mg is dissolved in polyinosini, behind the mix homogeneously, adds gradually with good vitamin A 20,000 U of dissolve with ethanol, and adding distil water is mixed with solution 50ml again.
Embodiment 5
With oryzanol 100mg and metronidazole 250mg porphyrize, 20mg is dissolved in polyinosini, behind the mix homogeneously, add gradually with good vitamin A 50,000 U of dissolve with ethanol,, adding distil water is mixed with solution 50ml again.
Embodiment 6
Behind oryzanol 50mg and GBF skin growth factor 300mg porphyrize, with polyinosini 15mg, vitamin B
1300mg, vitamin B
6The 300mg injection is dissolved in together, behind the mix homogeneously, adds gradually with good vitamin A 30,000 U of dissolve with ethanol, and adding distil water is mixed with solution 50ml again.
Embodiment 7
Get polyinosini 20mg, vitamin A 50,000 U, vitamin B
1500mg, vitamin B
6500mg, oryzanol 100mg, GBF skin growth factor 500mg, metronidazole 500mg, eosin are an amount of.At first vitamin A and eosin are dissolved, after oryzanol, metronidazole porphyrize are ground with the GBF skin growth factor again, with polyinosini, vitamin B with ethanol
1, vitamin B
6Injection is dissolved in together, behind the mix homogeneously, gradually with dissolve with ethanol good vitamin A and eosin mix homogeneously, add distilled water again and make pale red solution 50ml, promptly get pharmaceutical composition of the present invention.The purpose that adds an amount of eosin is that medicinal liquid is made into redness, as the sign of the medicinal liquid that is used externally only.
Claims (7)
1, a kind of pharmaceutical composition for the treatment of acute radiodermatitis is characterized in that: its component is polyinosini 10-20mg, vitamin A 2-5 ten thousand U, oryzanol 10-100mg, and said components is mixed with the 50ml solution with an amount of distilled water and ethanol.
2, the pharmaceutical composition of treatment acute radiodermatitis according to claim 1 is characterized in that: also add vitamin B in the described component
1100-500mg.
3, the pharmaceutical composition of treatment acute radiodermatitis according to claim 1 is characterized in that: also add vitamin B in the described component
650-500mg.
4, the pharmaceutical composition of treatment acute radiodermatitis according to claim 1 is characterized in that: also add GBF skin growth factor 100-500mg in the described component.
5, the pharmaceutical composition of treatment acute radiodermatitis according to claim 1 is characterized in that: also add metronidazole 100-500mg in the described component.
6, the pharmaceutical composition of treatment acute radiodermatitis according to claim 1 is characterized in that: can select vitamin B in the described component
1100-500mg, vitamin B
6Any two kinds, three kinds or four kinds among 50-500mg, GBF skin growth factor 100-500mg, the metronidazole 100-500mg add simultaneously.
7, the pharmaceutical composition of treatment acute radiodermatitis according to claim 1 is characterized in that: with polyinosini 10-20mg, vitamin A 2-5 ten thousand U, vitamin B
1100-500mg, vitamin B
650-500mg, oryzanol 10-100mg, GBF skin growth factor 100-500mg, metronidazole 100-500mg, eosin are an amount of, are mixed with solution 50ml with an amount of distilled water, ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100547785A CN101254203A (en) | 2008-04-10 | 2008-04-10 | Pharmaceutical combination for curing acute radiation dermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100547785A CN101254203A (en) | 2008-04-10 | 2008-04-10 | Pharmaceutical combination for curing acute radiation dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101254203A true CN101254203A (en) | 2008-09-03 |
Family
ID=39889528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100547785A Pending CN101254203A (en) | 2008-04-10 | 2008-04-10 | Pharmaceutical combination for curing acute radiation dermatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101254203A (en) |
-
2008
- 2008-04-10 CN CNA2008100547785A patent/CN101254203A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107970275A (en) | A kind of topical agent for treating tinea of feet and hands | |
| PL188153B1 (en) | Drug and manner of exterting a pharmacological effect on human organism by such drug | |
| CN101703651B (en) | Medicament for treating diabetic gangrene | |
| Demir et al. | Comparing two local anesthesia techniques for extracorporeal shock wave lithotripsy | |
| WO2012159444A1 (en) | Acupoint injection | |
| RU2454256C1 (en) | Method of treating cervical cancer | |
| CN101254203A (en) | Pharmaceutical combination for curing acute radiation dermatitis | |
| CN100502917C (en) | Powder medicine for clearing and activating the channels and collaterals and relieving pain | |
| CN105031254B (en) | A kind of paste and preparation method thereof for treating dermatitis | |
| CN112843146A (en) | New use of Chinese patent medicine sanhuang ointment | |
| CN1251753C (en) | Externally-applied medicine composition for treating mastoproliferation and its prepn | |
| CN107595873B (en) | It is a kind of treat tumor radiotherapy caused by radiodermatitis Percutaneously administrable preparation | |
| CN102266408B (en) | Use of gardenia extract and borneol effective ingredients in Chinese medicine preparation for intervening in cutaneous prutitus | |
| CN104510911B (en) | Treat pharmaceutical composition of non-infectious inflammation dermatoses and preparation method thereof | |
| CN1456170A (en) | External applied medicine composition containing vitamin B | |
| CN103655854A (en) | External application medicine for treating phlebitis caused by intravenous infusion and using method thereof | |
| CN103816539B (en) | Medicinal composition containing aminolevulinic acid | |
| CN101019998A (en) | Medicine for treating anorectal diseases | |
| CN1175836C (en) | Medicine for treating pile | |
| CN1247204C (en) | Medicine for treating beri-beri | |
| CN108721430A (en) | A kind of Chinese medicine composition and its preparation method and application for treating mild acne | |
| CN106880670A (en) | A kind of medicine for treating scabies | |
| CN106266152A (en) | A kind of pharmaceutical composition treating eczema and its production and use | |
| CN101259222A (en) | Medicaments for treating bone fracture bone fracture disease | |
| CN1064534C (en) | Medicine for skin disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080903 |